» Articles » PMID: 24889225

Multi-parameter Exploration of HIV-1 Virus-like Particles As Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques

Overview
Journal Virology
Specialty Microbiology
Date 2014 Jun 4
PMID 24889225
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Virus-like particles (VLPs) offer a platform to test the hypothesis that, since antibody binding to native envelope glycoprotein (Env) trimers results in HIV-1 neutralization, that native Env trimers presented in membranes may be useful for inducing neutralizing antibodies (nAbs) in a vaccine setting. So far, VLPs have not fulfilled this potential. Here, using a "shotgun" approach, we evaluated a wide cross-section of variables in a series of VLP immunizations. We identified 3 tentative leads. First, that VLP doses may not have been sufficient for optimal nAb induction. Second, that dampening the antigenicity of non-functional Env (for example uncleaved gp160) using either protease digests or IgG masking may be useful. Third, that guinea pig sera preferentially target non-conserved epitopes and exhibit relatively high background activity, suggesting that rabbits may be preferable as small animal vaccine models. Recent immunogenicity studies in rabbits appear to bear out all 3 of these leads.

Citing Articles

Evaluation of the Thermal Stability of a Vaccine Prototype Based on Virus-like Particle Formulated HIV-1 Envelope.

Aguado-Garcia D, Olvera A, Brander C, Sanchez-Merino V, Yuste E Vaccines (Basel). 2022; 10(4).

PMID: 35455233 PMC: 9029469. DOI: 10.3390/vaccines10040484.


Cross-Neutralizing CRF01_AE-Infected Plasma from Malaysia Targets CD4-Binding Site of Human Immunodeficiency Virus Type-1 Envelope Glycoprotein.

Ng Q, Tee K, Binley J, Tong T AIDS Res Hum Retroviruses. 2021; 38(2):162-172.

PMID: 34006141 PMC: 9206480. DOI: 10.1089/AID.2020.0299.


Decorated and Encapsulated: Virus-Like Particles Against Viral Infections.

Temchura V Vaccines (Basel). 2021; 9(3).

PMID: 33803636 PMC: 8002974. DOI: 10.3390/vaccines9030273.


Immunogenicity of HIV-1-Based Virus-Like Particles with Increased Incorporation and Stability of Membrane-Bound Env.

Gonelli C, King H, Mackenzie C, Sonza S, Center R, Purcell D Vaccines (Basel). 2021; 9(3).

PMID: 33801906 PMC: 8002006. DOI: 10.3390/vaccines9030239.


Efficiently cleaved HIV-1 envelopes: can they be important for vaccine immunogen development?.

DAS S, Kumar R, Ahmed S, Parray H, Samal S Ther Adv Vaccines Immunother. 2020; 8:2515135520957763.

PMID: 33103053 PMC: 7549152. DOI: 10.1177/2515135520957763.